| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Annalisa Marcuzzi | Q58493836 |
| Liza Vecchi Brumatti | Q37372559 | ||
| Lorenzo Monasta | Q37372619 | ||
| Elisa Piscianz | Q42231987 | ||
| Erica Valencic | Q42231997 | ||
| P2093 | author name string | Alberto Tommasini | |
| P2860 | cites work | Liver transplantation followed by allogeneic hematopoietic stem cell transplantation for atypical mevalonic aciduria | Q83615404 |
| Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study | Q84052223 | ||
| Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study | Q84614866 | ||
| Inflammation. Potent small molecule extinguishes the NLRP3 inflammasome | Q86860088 | ||
| ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs | Q94033839 | ||
| Cholesterol metabolism and immunity. | Q54310053 | ||
| Systemic and neuronal inflammatory markers in a mouse model of mevalonate kinase deficiency: a strain-comparative study. | Q54393387 | ||
| Type I interferonopathies: a novel set of inborn errors of immunity | Q56923635 | ||
| Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies? | Q56940101 | ||
| A role for geranylgeranylation in interleukin-1beta secretion | Q79318151 | ||
| (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase | Q79750026 | ||
| Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease | Q24601772 | ||
| Regulation of type I interferon responses | Q26853177 | ||
| A century of cholesterol and coronaries: from plaques to genes to statins | Q28080618 | ||
| B cells responses and cytokine production are regulated by their immune microenvironment | Q28083170 | ||
| Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus | Q28212039 | ||
| Hyper-IgD syndrome/mevalonate kinase deficiency: what is new? | Q28262203 | ||
| Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases | Q28263484 | ||
| The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes | Q28478561 | ||
| Fate of lymphocytes after withdrawal of tofacitinib treatment | Q28538586 | ||
| Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryl-CoA reductase gene | Q28585227 | ||
| Lapaquistat Acetate: Development of a Squalene Synthase Inhibitor for the Treatment of Hypercholesterolemia | Q29300690 | ||
| Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. | Q30967810 | ||
| Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease | Q33213858 | ||
| Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 | ||
| Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis | Q33397838 | ||
| Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome | Q33744674 | ||
| Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls | Q33843390 | ||
| Cryopyrinopathies: update on pathogenesis and treatment. | Q34013074 | ||
| Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms | Q34021151 | ||
| Averting inflammation by targeting the cytokine environment | Q34135558 | ||
| Activated STING in a vascular and pulmonary syndrome | Q34241214 | ||
| IL-1 blockade in autoinflammatory syndromes | Q34262561 | ||
| Lupus nephritis: a critical review | Q34299943 | ||
| Total synthesis of the squalene synthase inhibitor zaragozic acid C. | Q34382154 | ||
| Interferon-stimulated genes: a complex web of host defenses | Q34405609 | ||
| Fifty years of anti-ds DNA antibodies: are we approaching journey's end? | Q34628039 | ||
| Embryonic lethality and defective neural tube closure in mice lacking squalene synthase. | Q52173967 | ||
| Systemic lupus erythematosus. | Q53495545 | ||
| Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. | Q34659689 | ||
| Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies | Q34802959 | ||
| Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). | Q35016969 | ||
| Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate | Q35048395 | ||
| 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome | Q35050189 | ||
| Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations | Q35145346 | ||
| An expanding role for interleukin-1 blockade from gout to cancer | Q35219001 | ||
| Small-molecule control of cytokine function: new opportunities for treating immune disorders | Q35252669 | ||
| STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. | Q35263440 | ||
| Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside | Q35309470 | ||
| A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. | Q35350543 | ||
| A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients | Q35484320 | ||
| Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis | Q35568194 | ||
| Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus | Q35577284 | ||
| STING Negatively Regulates Double-Stranded DNA-Activated JAK1-STAT1 Signaling via SHP-1/2 in B Cells | Q35644477 | ||
| Animal Models of Interferon Signature Positive Lupus | Q35686914 | ||
| Cytokine levels in the serum of healthy subjects | Q36711758 | ||
| Dysfunctional interferon-alpha production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus | Q36757055 | ||
| Dynamic regulatory network controlling TH17 cell differentiation | Q36799525 | ||
| Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases | Q36816872 | ||
| Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. | Q36816882 | ||
| Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study | Q36844513 | ||
| Anti-inflammatory Agents: Present and Future | Q37118156 | ||
| The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases | Q37270409 | ||
| Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus | Q37298794 | ||
| Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. | Q37319117 | ||
| Glyburide inhibits the Cryopyrin/Nalp3 inflammasome | Q37387873 | ||
| Prevalence and burden of pediatric-onset systemic lupus erythematosus | Q37777642 | ||
| Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options. | Q37795641 | ||
| Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response | Q37811988 | ||
| Biologic drugs in autoinflammatory syndromes | Q38033874 | ||
| Targeted therapies in systemic lupus erythematosus | Q38130443 | ||
| Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis | Q38181610 | ||
| Diagnostic criteria for systemic lupus erythematosus: a critical review | Q38181673 | ||
| The hereditary autoinflammatory disorders uncovered | Q38242430 | ||
| Type I interferonopathies: mendelian type I interferon up-regulation | Q38281134 | ||
| Current role of rituximab in systemic lupus erythematosus | Q38293284 | ||
| Monogenic autoinflammatory diseases: Cytokinopathies | Q38392859 | ||
| Statins and the liver | Q38457875 | ||
| One year in review 2015: systemic lupus erythematosus. | Q38536682 | ||
| A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus | Q38537618 | ||
| Inherited anomalies of innate immune receptors in pediatric-onset inflammatory diseases | Q38565727 | ||
| Alendronate, a double-edged sword acting in the mevalonate pathway. | Q38861481 | ||
| The exonuclease Trex1 restrains macrophage proinflammatory activation. | Q39064224 | ||
| ASC speck formation as a readout for inflammasome activation | Q39126034 | ||
| Lovastatin-induced apoptosis is modulated by geranylgeraniol in a neuroblastoma cell line | Q39320557 | ||
| Cryopyrin-associated periodic syndrome. | Q40180765 | ||
| Manipulation of isoprenoid biosynthesis as a possible therapeutic option in mevalonate kinase deficiency | Q40262548 | ||
| Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. | Q40501564 | ||
| Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. | Q40793696 | ||
| Cutaneous manifestations and histologic findings in the hyperimmunoglobulinemia D syndrome. International Hyper IgD Study Group | Q40803039 | ||
| Different presentations of mevalonate kinase deficiency: a case series | Q41301782 | ||
| Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy | Q42162220 | ||
| IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients | Q42482233 | ||
| Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: in vitro and in vivo approaches. | Q43141414 | ||
| Lovastatin induces apoptosis through the mitochondrial pathway in an undifferentiated SH-SY5Y neuroblastoma cell line | Q43180081 | ||
| Dimethyl sulfoxide inhibits NLRP3 inflammasome activation | Q44976570 | ||
| Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. | Q45943683 | ||
| A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). | Q46055629 | ||
| Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome | Q46896304 | ||
| Mevalonate kinase deficiency nomenclature | Q47843422 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | catalysis | Q82264 |
| anti-inflammatory agent | Q581996 | ||
| organic chemistry | Q11351 | ||
| P304 | page(s) | 21277-93 | |
| P577 | publication date | 2015-01-01 | |
| 2015-09-07 | |||
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies | |
| P478 | volume | 16 |
Search more.